SPEXIS
Spexis is the operator of a bioengineering business that concentrates on creating treatments for bacterial infections that are resistant to common antibiotics. T to help patients with chronic, recurrent, and life-threatening pulmonary infections, the business develops medications targeted toward therapy for cystic fibrosis, non-CF bronchiectasis, and non-tuberculosis mycobacterial infections. Their in-house scientist is in charge of their drug discovery and research projects, utilizing their discovery platforms and working with renowned research institutions across the world.
SPEXIS
Industry:
Biotechnology Clinical Trials Life Science Product Research
Founded:
1996-01-01
Address:
Allschwil, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.spexisbio.com
Total Employee:
11+
Status:
Active
Contact:
+41 61 567 16 00
Official Site Inspections
http://www.spexisbio.com Semrush global rank: 7.06 M Semrush visits lastest month: 615
- Host name: s062.cyon.net
- IP address: 149.126.4.71
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Spexis"
Spexis – Delivering Continuous Hope for Rare Disease …
And in many therapeutic indications such as solid tumors, hematologic malignancy and stem cell mobilization. Although a P3 trial in metastatic breast cancer read out negatively in mid-2021, Spexis believes there may be …See details»
Annual Report 2021 - spexisbio.com
The Cystic Fibrosis Foundation the leading patient advocacy and philanthropic organization servicing the needs of CF patients and their caretakers worldwide - also participated in our …See details»
Spexis AG – Swiss Biotech
Spexis AG (SIX:SPEX) is a clinical-stage biotech company focused on first-in-class macrocyclic drugs for cancer & rare diseases. >25 years and $400M of R & D has resulted in three clinical …See details»
Spexis AG - LinkedIn
Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are urgently ...See details»
Spexis AG (SWX:SPEX) Company Profile & Description - Stock …
Jul 31, 2024 Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer.See details»
Spexis - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
Spexis - SPRIM Global Investments
New York. 545 West 25th Street, 20th Floor New York, NY, USA 10001See details»
Spexis 2025 Company Profile: Stock Performance
The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research …See details»
Corporate Governance* – Spexis
Annual General Meetings. June 28, 2024 Annual General Meeting. Invitation AGM 2024 (PDF) June 26, 2023 Annual General Meeting. Invitation AGM 2023 (PDF)See details»
Spexis Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
For further information please contact: For Investors: Martin Jakobovic Head of Finance & acting Chief Financial Officer Spexis AG +41 61 567 1600 [email protected] For Media: Dr. …See details»
Spexis - Overview, News & Similar companies | ZoomInfo.com
Spexis contact info: Phone number: +41 615671600 Website: www.spexisbio.com What does Spexis do? Spexis is a company that specializes in the manufacturing of pharmaceuticals with …See details»
Spexis - Company Profile - Tracxn
Feb 25, 2025 Developer of antibiotic therapeutics for the treatment of cancer and rare diseases. The product pipeline of the company includes ColiFin for cystic fibrosis, EBX-002, a …See details»
Spexis CEO and Key Executive Team | Craft.co
Spexis's CEO & Chairman is Jeffrey D. Wager. Other executives include Stephan Wehselau, Chief Operating Officer; Dennis Ausiello, Vice Chairman and 5 others. See the full leadership …See details»
Spexis announces sale of preclinical antibiotics program to Basilea
Jan 15, 2024 In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are …See details»
Corporate Presentation – Spexis
© 2025, Spexis Ltd., Hegenheimermattweg 125, 4123 Allschwil, Switzerland, T: +41 61 567 16 00, [email protected] – Disclaimer – Privacy Rules – DisclosureSee details»
Spexis Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Spexis has 5 employees at their 1 location. See insights on Spexis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Spexis announces sale of preclinical antibiotics program to Basilea
Jan 15, 2024 In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, ... www.spexisbio.com.See details»
Spexis to present at BIO-Europe® 2022 - Markets Insider
Oct 18, 2022 [email protected]: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 [email protected] Europe Raimund Gabriel MC Services [email protected] …See details»
Investor Relations (placeholder) – Spexis
© 2025, Spexis Ltd., Hegenheimermattweg 125, 4123 Allschwil, Switzerland, T: +41 61 567 16 00, [email protected] – Disclaimer – Privacy Rules – DisclosureSee details»